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Background: The Danning tablets (DNts) is commonly prescribed in China as a cholagogic formula. Our previous
studies showed that DNts exerted the protective effect on α-naphthylisothiocyanate (ANIT)-induced liver injury with
cholestasis in a dose-dependent mannar. However, the detailed molecular mechanisms of DNts against ANIT-induced
cholestasis are still not fully explored.
Methods: Danning tablet (3 g/kg body weight/day) was administered orally to experimental rats for seven days
before they were treated with ANIT (60 mg/kg daily via gastrogavage) which caused cholestasis. Serum levels of
alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (T-Bil),
direct bilirubin (D-Bil) and total bile acid (TBA) were measured to evaluate the protective effect of Danning tablet
at 12, 24 and 48h after ANIT treatment. Meanwhile, total bilirubin or total bile acid in the bile, urine and liver were
also measured at 48h after ANIT treatment. Furthermore, the hepatic or renal mRNA and protein levels of
metabolic enzymes and transports were investigated to elucidate the protective mechanisms of Danning tablet
against ANIT-induced cholestasis.
Results: In this study, we found that DNts significantly attenuated translocation of multidrug resistance-associated protein
2 (Mrp2) from the canalicular membrane into an intracellular and up-regulated the hepatic mRNA and protein expressions
of metabolic enzymes including cytochrome P450 2b1(Cyp2b1) and uridine diphosphate-5¢- glucuronosyltransferase
(Ugt1a1)) and transporters including bile salt export pump (Bsep) and multidrug resistance protein 2 (Mdr2)) as well as
renal organic solute transporter beta (Ostβ), accompanied by further increase in urinary and biliary excretion of bile acid
and bilirubin.
Conclusions: DNts might promote bile acid and bilirubin elimination by regulating the expressions of hepatic and renal
transporters as well as hepatic metabolic enzymes.
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Cholestasis, an impairment or cessation in the flow of bile,
leads to hepatic and systemic accumulation of potentially
toxic biliary compounds such as bile acids and bilirubin,
resulting in acute liver toxicity, jaundice and hypercholes-
terolemia, and then aggravated outcomes just like hepatic
fibrosis, cirrhosis and clinical signs of liver failure [1,2]. It
has been reported that cholestasis may develop from viral* Correspondence: yangli7951@hotmail.com; wangzht@hotmail.com
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unless otherwise stated.hepatitis or the administration of certain drugs and hor-
mones or mechanical obstructions in the extrahepatic
bile ducts [2].
The mechanisms of cholestasis might be related to
the altered expressions of hepatic metabolic enzymes
and transporters [3,4]. Drug metabolic enzymes (DMEs)
play central roles in the metabolism, elimination and/or
detoxification of xenobiotics or exogenous compounds
introduced into the body [5]. Metabolic enzymes in the
liver are classified into phase 1, such as cytochrome P450
(Cyp) [5], and phase 2, such as uridine diphosphate-5¢-
glucuronosyltransferase (Ugt) [6], sulfotransferase (Sult)d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Ding et al. BMC Complementary and Alternative Medicine 2014, 14:249 Page 2 of 12
http://www.biomedcentral.com/1472-6882/14/249[7]. Several transporters which are related to cholestasis
have been identified in hepatocytes, such as multidrug
resistance protein (Mdr), bile salt export pump (Bsep),
multidrug resistance associated protein (Mrp) [8,9], or-
ganic solute transporter alpha/beta (Ostα/β) [10], Na+
taurocholate cotransporting polypeptide (Ntcp) [9], and
organic anion transporting polypeptide (Oatp) [11].
ANIT is well konwn as a cholestatic compound
and has been widely used as a model component for
induction of intrahepatic cholestasis [12]. In rodents, α-
naphthylisothiocyanate (ANIT) is a widely used chemical
to mimic human intrahepatic cholestasis [13]. It has
been reported that the mRNA expressions of metabolic
enzymes and transporters changed in ANIT-induced
cholestasis model [14,15].
Danning tablets (DNts), as a composite prescription of
traditional Chinese medicine, consisting of seven medi-
cinal materials: Radix et Rhizoma Rhei, Rhizoma et Radix
Polygoni Cuspidati, Pericarpium Citri Reticulatae, Pericar-
pium Citri Reticulatae Viride, Radix Curcumae, Fructus
Crataegi and Rhizoma Imperatae [16], have been proved
to be effective for treatment of cholecystitis and preven-
tion the formation of cholesterol gallstone in human [17].
We previously showed that the protective effect of DNts
on ANIT-induced liver injury was probably due to its at-
tenuation of oxidative stress disruption in the liver tissues
and neutrophil infiltration [18]. However, the underlying
mechanisms about protective effect of DNts on ANIT-
induced cholestasis are not explored yet.
In this study, in order to clarify the possible mechanisms
for protective effect of DNts on ANIT-induced cholestasis,
we investigated the mRNA and protein expressions of
metabolic enzymes and transports which were relevant to
the excretion of bile acids and bilitubin.Methods
Drugs, chemicals and reagents
DNts were friendly provided by Shanghai Hutchison
Pharmaceuticals (Shanghai, China) at July 2010. Standard
compounds (emodin, aleo-emodin, rhein, chrysophanol,
physcion) purchased from National Institute for the Con-
trol of Pharmaceutical and Biological Products (Beijing,
China). ANIT were purchased from Sigma-Aldrich (St.
Louis, USA). The purity of each compound was deter-
mined to be above 98% by HPLC analysis. Ammonium
acetate, formic acid, acetonitrile and methanol (HPLC-
grade) were purchased from Fisher Scientific (Nepean,
Ont., Canada). Ultrapure water was prepared by a Milli-
Q50 SP Reagent Water System (Millipore Corporation,
MA, USA) for the preparation of samples and buffer solu-
tions. Serum levels of ALT, AST, ALP, T-Bil, D-Bil and
TBA were determined using a commercially available test
kits (SHINO-TEST Corporation, Japan) with HITACHI7080 Automatic Analyzer system (Japan). All other chemi-
cals and solvents used were of analytical grade.
Chromatography analysis
In order to make quality control of DNts and improve the
repeatability of experiments, the contents of five anthra-
quinones, which might be the main active components
contained in DNts, were determined by HPLC analysis.
The determination was performed on the Agilent 1100
chromatographic system, consisting of a solvent degasser,
aquaternary gradient pump before column, diodearray
detector (DAD) and a data station with analytical soft-
ware of Chemstation 8.03 (Agilent, Inc., USA). The
method to analyze the anthraquinones in DNts used in
this study was well established according to the China
Pharmacopoeia Committee (2010 edition) [15]. All the
separation was performed on a Kromasil® C18 analytical
column (250 mm × 4.6 mm, 5 μm) and maintained at
25°C. The mobile phase was a mixture of methanol–
0.1% phosphoric acid aqueous solution (85:15, v:v) with
the flow rate of 1ml/min. The injection volume was 10
μl and the detection wavelength was set at 254 nm. The
standard solutions of five AQs (aloe-emodin 15 μg/mL,
emodin 8 μg/mL, chrysophanol 40 μg/mL, rhein 2 μg/mL
and physcion 10 μg/mL) were prepared with methanol.
Samples were prepared according to China Pharmacopoeia
Committee, 2010.
Animal experimental design
Male Wistar rats weighing 220 ± 20 g were used in this
study. All rats were maintained in 12-h light/dark cycles
and given free access to water and standard chow. All
animal care and use procedures were in accordance with
the guidelines of the Institutional Animal Care and Use
Committee and were approved by the Animal Experimen-
tation Ethics Committee at the Shanghai University of
Traditional Chinese Medicine under the guidelines of the
National Health and Medical Research Council of China.
The animals were randomly divided into the following
treatment groups (n = 8 rats/group): (1) Control group
(Vehicle group), (2) ANIT group, (3) DNts + ANIT group,
(4) DNts group. The rats in Control and ANIT groups
were pretreated with 0.5% sodium carboxymethylcellulose
(CMCNa) solution alone; the other two groups were
intragastrically treated daily with the powder of DNts
which was suspended in 0.5% CMCNa solution at a dose
of 3.0 g/kg B.W. for 9 consecutive days, respectively. At
12 h after the seventh administration of test drugs,
groups 2 and 3 were intragastrically received ANIT dis-
solved in peanut oil at a dose of 60 mg/kg B.W.. The
Control and DNts groups were intragastrically given the
peanut oil in an equal volume as for groups 2 and 3
(5 ml/kg B.W.). Blood samples were collected from
inferior vena cava at 0, 12, 24, and 48 h after ANIT
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for later analysis of biochemical parameters.
At 48 h post ANIT administration, the rats were anaes-
thetized with urethane (1 g/kg B.W., i.p.). The bile duct
was cannulated with Closed IV Catheter System (inner
diameter, 0.36 mm; outer diameter, 0.71 mm; Becton,
Dickinson and Co., Suzhou, China). After the operation,
Bile specimens were collected into tubes for 1 h, as pre-
viously described [18]. Then, the animals were killed by
decapitation, the liver and kidney of rats were collected
and stored in liquid nitrogen for analysis of enzyme
levels and gene or protein expressions.
Serum biochemistry analysis
Serum was collected at 0, 12, 24, 36 and 48 h after ANIT
treatment. The serum levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), alkaline phosphat-
ase (ALP), total bilirubin (TBil), direct bilirubin (DBil) and
total bile acid (TBA) were determined using commercially
available clinical test kits and an automatic biochemical
analyzer (HITACHI 7080, Japan).
Bile acid and bilirubin analysis
Bile acids were extracted from liver samples using 75%
ethanol, as previously described [19]. Total bile acids in
the liver, bile, and urine were measured using commercial
assay kits from the Jiancheng Institute of Biotechnology
(Nanjing, China). Total bilirubin in the bile and urine
were also measured with commercial assay Kits from
the Jiancheng Institute of Biotechnology (Nanjing, China)
in accordance with the manufacturer’s protocols.
Quantitative real-time PCR analysis
Total RNA from liver and kidney were extracted using
TRIzol reagent (Invitrogen, CA, USA) according to the
manufacturer’s instructions. Quantitative real-time PCR
(qPCR) was performed using cDNA generated from 3 μg
total RNA with the SuperScript II Reverse Transcriptase
kit (Invitrogen, CA, USA). PCR reactions were carried out
using SYBR Premix ExTaq Mix (Takara Biotechnology,
Japan) in an ABI Prism 7900HT Sequence Detection Sys-
tem (Applied Biosystems, CA). The primer sequences
were listed in Table 1. Thermal cycler parameters were as
follows: 1 cycle of 95°C for 30 s, 40 cycles of denaturation
(95°C, 5 s) and combined annealing/extension (60°C,
30 s). Gene expression changes were calculated by the
comparative Ct method and the values were normalized
to endogenous reference Gapdh.
Preparation of liver membranes and for Western analysis
Plasma membranes or intracellular microsomal mem-
branes were separated by differential centrifugation. Por-
tions of the liver were homogenized with a teflon pestle
(20 strokes at 3,000 rpm) in 0.3 mol/L sucrose containing0.1 mmol/L PMSF, 25 μg/mL leupeptin, 5μg/mL aprotinin,
and 5 μg/mL pepstatin A (50 mg liver/mL buffer) ac-
cording previous report [20]. The homogenate was used
for membrane preparation as described previously [21].
Protein concentrations were measured according to the
method of BCA [22] using bovine serum albumin as a
standard.
Western blot studies
Immunoblotting and subsequent densitometry were per-
formed with mixed plasma membranes, and intracellular
membranes were incubated with antibodies against Mrp2
(ab3373, 1:50, abcam) and Na+/K+-ATPase (#3010, 1:1000,
Cell Signaling). Moreover, the crude membranes were
prepared according to the protocol of protein extraction
kit (BioVision, USA). Equal amounts of crude membranes
(40 μg/lane) were separated on 6%-15% SDS-PAGE and
transferred to nitrocellulose membrane. Membranes were
blocked in 5% skim milk and incubated with antibodies
against Bsep (sc-25571, 1:200, Santa Cruz), Ntcp (#6522-1,
1:1000, epitomics), Oatp1 (LS-C113034-50, 1:1000, Life-
Span BioSciences), Mrp3(ab3375, 1:50, abcam), Mdr2
(SAB2100008, 1:1000, sigma) and Na+/K+-ATPase (#3010,
1:1000, Cell Signaling), respectively. Blots were incu-
bated with horseradish peroxidase conjugated secondary
antibodies (Santa Cruz) and developed by ECL detection
regents (Amersham). The protein bands were quantified
by the average ratios of integral optic density (IOD) fol-
lowing normalization to Na+/K+-ATPase expression.
Determination of liver Ugt1a1, Cyp2b1 and Sult2a1 levels
Liver segments were homogenized in ice-cold PBS. The
homogenates were centrifuged at 3,000 g for 10 min and
the supernatants were assayed for the determination of
levels of the Ugt1a1, Cyp2b1 (CUSABIO, CN) and Sult2a1
(USCN Life Science,CN) by using ELISA kits according to
the manufacturer’s protocols. The results are expressed as
folds of control.
Statistical analysis
The data were analyzed using a SPSS 16.0 statistical pack-
age. Multiple comparisons were performed by one-way
analysis of variance (ANOVA) followed by LSD t-test.
Difference was considered statistically significant when
p ≤ 0.05, and very significant when p ≤ 0.01 and p ≤ 0.001.
All results are presented as the mean ± SD.
Results
HPLC determination of anthraquinones in DNts
The major compounds in DNts were anthraquinones
and analyzed with HPLC- UV. By referring to standards,
HPLC chromatogram analysis of three batches of DNts
showed that the main anthraquinones in DNts were aloe-
emodin, emodin, chrysophanol and physcion (Figure 1);
Table 1 Primer sequences used for quantitative real-time PCR in this study
Gene (GenBank accession no.) Sequence (5’–3’)
Asbt XM_003751634 GGATAGATGGTGACATGGAC (fw)
GAAACAGGAATAACAAGCGC (rev)
Bsep U69487 CTGATGCTTATGGGAGGCGTAT (fw)
TCTGGTGGAAGGAGCTGTTGATC (rev)
Cyp2b1 NM_001134844 GCTATGGTTTCCTGCTGATGCTC (fw)
GACTCTGTGTGGTACTCCAATAGGG (rev)
Mdr2 NM_012690 GTTGAAATGAAAATGTTGGCTGG (fw)
ATGCCGTAGATGTGAGCCTTCC (rev)
Mrp2 NM_012833 TCAGATGAGGAGGTTTGGAGGG (fw)
CTCTGTCACTTCGGATAACAACCC(rev)
Mrp3 NM_080581 TGAAGAGACTGGAATCCGTTAGCC (fw)
GTTGGAGGCGATGTAAGGATAAGTG (rev)
Mrp4 NM_133411 GACACCAAAAACGCGAACGG (fw)
ACAAGGACATAGAACACCAGCAGG (rev)
Ntcp NM_017047 CTACCTCCTCCCT GATGCCCTT (fw)
TGAGGATGGTAGAACAGAGTTGAATG (rev)
Oatp1 NM_017111 TGCCTGCCTTCTTCATTCTGATACT (fw)
GTTTTCAGTTCTCCGTCATTCTCG (rev)
Ostα NM_001107087 TCCTCTGTCCCTGAGCCTTATC (fw) TCTCTGCTTTCACCATTTATTACAA (rev)
Ostβ XM_238546 TGCTTTGGTATTTCCGTTC (fw)
TCTGGCATTCCGTTGTCTT (rev)
Sult2a1 NM_131903 ATCAAAAAGAAAGGACCACGACTC (fw)
AACCATTCAACATAAGTTCCCAGTG (rev)
Ugt1a1 NM_012683 TGAAGCCTATGTCAACGCCTC (fw)
CGATGGTCTAGTTCCGGTGTAGC (rev)
Gapdh NM_017008 AGAAGGTGGTGAAGCAGGCATC (fw)
CGAAGGTGGAAGAGTGGGAGTTG (rev)
fw: forward primer; rev: reverse primer; bp: base pair.
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13.452 mg/g, 1.341 mg/g, and 2.290 mg/g, respectively,
and summarized in Table 2.
Effects of DNts on the levels of serum enzymes and
components in ANIT-induced cholestasis rats
To examine the effects of DNts on ANIT mediated hep-
atotoxicity and cholestasis, plasma levels of ALT, AST,
ALP, TBil, DBil and TBA were quantified as measures of
liver injury with cholestasis. In both ANIT group and
DNts + ANIT group, serum levels of ALT, AST, ALP,
TBIL, DBIL and TBA were unchanged at 12 h, but sig-
nificantly elevated at 24 h and 36h and peaked at 48 h
after ANIT treatment as compared to those in the ve-
hicle group. However, the pretreatment of DNts at dose
of 3 g/kg B.W. significantly reversed ANIT-induced ele-
vation of TBIL (Figure 2; p < 0.01) at 36 h as well as ALT,
AST, ALP, TBIL, DBIL and TBA (Figure 2; p < 0.01) at48 h after ANIT treatment. In addition, DNts treated
alone (3 g/kg B.W.) did not significantly affect serum
ALT, AST, ALP, TBil, DBil and TBA levels as compared
to the vehicle group (Figure 2). The above results are
consistent with our previous report [18].
Effects of DNts on the levels of bile acids and bilirubin in
the liver, urine, and bile after ANIT treatment
The concentrations of bile acid or bilirubin in the liver, bile,
and urine were quantified at 48 h after ANIT treatment.
Hepatic bile acid pool size were increased significantly
in ANIT-treated rats (Figure 3A; p < 0.01). Meanwhile,
urinary excretion of bile acids and bilirubin in the rats
of ANIT-treated group were also increased after ANIT
treatment (Figure 3D, 3E; p < 0.01). In addition, biliary
bilirubin concentrations in ANIT-treated rats were ele-
vated significantly (Figure 3C; p < 0.01). In contrast, bil-
iary bile acid pool size were dramatically reduced by
A.
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Figure 1 HPLC chromatogram of mixed standards (A) and DNts (B).
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significantly attenuated the ANIT-induced accumulation
of hepatic bile acids and significantly increased the bile
acid and bilirubin excretion of urine and bile in ANIT-intoxicated rats (Figure 3A-3E; p < 0.01, p < 0.05). DNts
treated alone (3 g/kg B.W.) did not significantly affect
the bile acid and bilirubin pool size in the liver, bile and
urine as compared to the vehicle group (Figure 3). These
Table 2 The contents of five anthraquinones in DNts
Compound RT Content (mg/g) SD
Aleo-emodin 4.774 0.445 0.035
Emodin 9.439 13.452 0.843
Chrysophanol 13.799 1.341 0.094
Physcion 19.255 2.290 0.168
Rhein - - -
RT:retention time.
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acid and bilirubin elimination to attenuate cholestasis.Effects of DNts on gene expressions of transporter and
metabolic enzyme in ANIT-induced cholestasis rats
Firstly, we examined hepatic mRNA expressions of baso-
lateral transporters after ANIT treatment (Figure 4A). In
agreement with previous observations [14,15], the mRNA
levels of basolateral uptake transporters Ntcp and Oatp1
were significantly down-regulated by ANIT (Figure 4A;
p < 0.01). In contrast, the mRNA levels of basolateral
efflux transporter Mrp3, MRP4, Ostβ were markedly
up-regulated in ANIT-intoxicated rats (Figure 4A, 4B;
p < 0.01). However, Both ANIT and DNts did not affect
the mRNA expressions of Ostα (Figure 4B). DNts pretreat-
ment significantly reversed ANIT-induced down-regulation
of the Ntcp (p < 0.05) and Oatp1 mRNA levels (p < 0.01),
but did not affect the mRNA levels of Mrp3, Mrp4 and
Ostβ in ANIT- intoxicated rats (Figure 4A, 4B).Figure 2 Serum levels of (A) ALT, (B) AST, (C) ALP, (D) T-Bil, (E) D-Bil a
48 h after ANIT treatment. Data represent means ± S.D. (n = 8 for each gro
control group; #p < 0.05, ##p < 0.01 vs. the ANIT-treated group.Secondly, hepatic gene expressions of canalicular
efflux transporters were determined (Figure 4B). The
mRNA level of Mdr2 was significantly up-regulated by
ANIT (Figure 4C; p < 0.01). There were no changes in
mRNA levels for Mrp2 and Bsep after ANIT treatment
(Figure 4C). DNts pretreatment resulted in substantial
elevation of Mdr2 and Bsep mRNA levels in ANIT-
intoxicated rats (Figure 4C; p < 0.05).
Thirdly, we examined the hepatic gene expressions of
metabolic enzymes such as Cyp2b1, Ugt1a1 and Sult2a1
(Figure 4D). The mRNA levels of Cyp2b1 and Ugt1a1 in
ANIT-treated rats were significantly decreased (Figure 4D;
p < 0.01). DNts pretreatment significantly reversed ANIT-
induced reduction of the Cyp2b1 and Ugt1a1 mRNA
levels (Figure 4D; p < 0.05), but did not affect the mRNA
expression of Sult2a1 in ANIT-intoxicated rats (Figure 4D).
Otherwise, DNts pretreatment alone did not affect mRNA
levels of Oatp1, Ntcp, Mrp3, Bsep, Mdr2, Mrp2, Cyp2b1,
Ugt1a1 and Sult2a1 (Figure 4D).
In addition, as urinary excretion of bile acids and
bilirubin were significantly higher in ANIT-intoxicated
rats, we next determined the expression of renal bile
acid transporters (Figure 5A-F). ANIT treatment mark-
edly increased the mRNA levels for bile acid export
transporter Mrp2, Mrp3, MRP4 and Ostβ (Figure 5A,
5B, 5C and 5F; p < 0.01). In contrast, the main reuptake
transporter Asbt was down-regulated after ANIT treat-
ment (Figure 5D; p < 0.01). Pretreatment with DNts re-
sulted in further significantly increasing of renal Mrp3
and Ostβ mRNA levels and significantly reversing thend (F) TBA were measured in each group at 0, 12, 24, 36 and
up). Significant difference between two groups. *p < 0.05, **p < 0.01 vs.
Figure 3 Altered levels of bile acids and bilirubin after ANIT treatment. (A) hepatic bile acids, (B) biliary bile acids, (C) biliary bilirubin, (D)
urinary bile acids, and (E) urinary bilirubin were measured in each group 48 h after ANIT treatment. Data represent means ± S.D. (n = 8 for each
group). Significant difference between two groups. *p < 0.05, **p < 0.01 vs. control group; #p < 0.05, ##p < 0.01 vs. the ANIT-treated group.
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(Figure 5B,F; p < 0.05). Both ANIT and DNts treatment
did not affect the mRNA expression of Ostα (Figure 5E).
DNts pretreatment alone did not affect the mRNA
levels of renal Mrp2, Mrp3, MRP4, Asbt, Ostα and Ostα
(Figure 5A-F).
Effect of DNts on protein expressions of Ntcp, Oatp1,
Mrp3, Mdr2, Bsep and Mrp2 in the liver membranes of
ANIT-induced cholestasis rats
Furthermore, we investigated the protein expressions
of hepatic transporters to confirm the results of mRNA
levels. The protein levels of basolateral uptake transporter
Ntcp and Oatp1 were significantly downregulated in the
liver membranes of ANIT-intoxicated rats (Figure 6;
p < 0.01). In contrast, the protein expression of basolateral
efflux transporter MRP3 was significantly up-regulated
in the liver membranes of ANIT-intoxicated rats as
well as the canalicular efflux transporter Mdr2 (Figure 6;
p < 0.01). However, DNts pretreatment significantly up-
regulated the protein levels of Ntcp and Oatp1 (Figure 6;
p < 0.01, p < 0.05) and further increased the protein levels
of canalicular efflux transporter Mdr2 and Bsep (Figure 6;
p < 0.05), but did not affect the protein level of Mrp3 in
the hepatic membranes of ANIT-intoxicated rats. Other-
wise, both ANIT and DNts treatment did not affect theprotein level of Mrp2 in hepatic plasma Membranes
(Figure 7). Therefore, we evaluated whether ANIT could
lead to redistribution of the protein Mrp2 from plasma
to intracellular membranes. Mrp2 detection was increased
in hepatic intracellular membranes of ANIT-intoxicated
rats (Figure 7; p < 0.01). DNts pretreatment significantly
reversed ANIT-induced up-regulation of Mrp2 in intracel-
lular membranes (Figure 7; p < 0.01).
Effect of DNts on the protein levels of Cyp2b1, Ugt1a1
and Sult2a1 in the liver of ANIT-induced cholestasis rats
The protein levels of endogenous metabolic enzymes in
liver tissue microsomes was further confirmed. The pro-
tein levels of Cyp2b1 and Ugt1a1 in the model group were
obviously reduced (Figure 8; p < 0.01). But the hepatic
Sult2a1 level was not changed in ANIT-intoxicated rats
(Figure 8). Whereas, DNts treatment notably reversed the
decline of these metabolic enzymes except Sult2a1 com-
pared with that in ANIT-treated rats (Figure 8; p < 0.01).
Moreover, pretreatment of DNts alone did not affect the
hepatic protein levels of Cyp2b1, Ugt1a1 and Sult2a1
(Figure 8).
Discussion
The pretreatment of DNts significantly reversed ANIT-
induced elevation of serum ALT, AST, ALP, T-Bil, D-Bil
Figure 4 The effects of DNts on mRNA expressions of transporters and metabolic enzymes in the liver of ANIT-induced cholestasis rats.
Relative hepatic mRNA levels of (A) basolateral uptake transporters (Oatp1, Ntcp) and basolateral efflux transporters (Mrp3), (B) basolateral efflux
transporters (Mrp4, Ostα and Ostβ) (C) canalicular efflux transporters (Mrp2, Mdr2 and Bsep), and (D) bile acid-metabolizing enzymes (Cyp2b1,
Ugt1a1 and Sult2a1) were determined by qRT-PCR in liver samples isolated from rats treated with vehicle, DNts, ANIT or DNts + ANIT (n = 3 for
each group). Expression was normalized to Gapdh, and each bar represents the mean ± SD of three independent experiments. Significant
difference between two groups. *p < 0.05, **p < 0.01 vs. control group; #p < 0.05, ##p < 0.01 vs. the ANIT-treated group.
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ent with previous research [23]. We presented here the
evidence that DNts protected rats from the accumula-
tion of bile acids in the liver and subsequent develop-
ment of liver injury with cholestasis induced by ANIT,
in association with an augmentation of bile acid and bili-
rubin excretion of bile and urine.
In the current study, we further investigated whether
the protective effect of DNts against ANIT-induced cho-
lestasis might be related to the expression of metabolic
enzymes and transporters. The metabolic enzymes par-
ticipate in critical processes including the biosynthesis ofbile acids and the detoxification of accumulating biliary
compounds. The hepatic metabolic enzymes may render
hydrophobic substrates less toxic and better soluble for
biliary and urinary excretion via phase I hydroxylation
and phase II conjugation to counteract cholestatsis [24].
Our findings displayed that DNts pretreatment signifi-
cantly up-regulated both mRNA and protein expres-
sions of hepatic metabolic enzymes including Cyp2b1
and Ugt1a1 in ANIT-induced cholestasis rats. These
results indicated that the up-regulation of mRNA and
protein expressions of the phase I hydroxylation en-
zymes (Cyp2b1) and phase II conjugation enzymes
Figure 5 The effects of DNts on mRNA expressions of renal transporters (A) Mrp2, (B) Mrp3, (C) Mrp4, (D) Asbt, (E) Ostα and (F) Ostβ in
ANIT-induced cholestasis rats were determined by qRT-PCR (n = 3 for each group). Expression was normalized to Gapdh, and each bar
represents the mean ± SD of three independent experiments. Significant difference between two groups. *p < 0.05, **p < 0.01 vs. control group;
#p < 0.05, ##p < 0.01 vs. the ANIT-treated group.
Figure 6 The hepatic protein levels of transporters Oatp1, Ntcp, Mrp3, Mdr2 and Bsep were determined by Western blot (n = 3 for
each group). Quantification of the protein expressions was performed by densitometric analysis of the blots following normalization to Na+/K+-ATPase
expression. Each bar represents the mean ± SD of three independent experiments. Significant difference between two groups. *p < 0.05, **p < 0.01 vs.
control group; #p < 0.05, ##p < 0.01 vs. the ANIT-treated group.
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Figure 7 Effects of DNts on hepatic protein levels of Mrp2 in mixed plasma membranes and intracellular membranes were determined
by Western blot (n = 3 for each group). Quantification of the protein expressions was performed by densitometric analysis of the blots
following normalization to Na+/K+-ATPase expression. Each bar represents the mean ± SD of three independent experiments. Significant
difference between two groups. *p < 0.05, **p < 0.01 vs. control group; #p < 0.05, ##p < 0.01 vs. the ANIT-treated group.
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http://www.biomedcentral.com/1472-6882/14/249(Ugt1a1) induced by DNts might counteract cholestatic
liver damage by detoxification of accumulating biliary
compounds.
Basolateral uptake transporters, such as Ntcp and Oatps,
transport bile acids and organic anions from sinusoidal
blood into hepatocytes [9-11]. In contrast, basolateral ex-
port transporters, such as Mrp3, Mrp4 and Ostα/β trans-
port bilirubin glucuronide and bile acids, respectively,
from hepatocytes into blood during cholestasis [10,25].
Bile acids transport at canalicular membrane of the hep-
atocyte is mediated by ATP-binding cassette transporters,
including Bsep, Mrp2, and Mdr2 [26]. The export of toxic
bile acids by canalicular transporters is probably an alter-
native escape route during intrahepatic cholestasis [8]. At
48 h after ANIT treatment, we found that spontaneous
hepatic anticholestatic defenses which comprised down-
regulation of import systems (e.g., Ntcp, Oatp1) and
adaptive induction of basolateral alternative export
pump (e.g.,Mrp3) as well as the canalicular transporters,Figure 8 Effects of DNts on the levels of Cyp2b1, Ugt1a1 and Sult2a1
(A) Cyp2b1, (B) Ugt1a1 and (C) Sult2a1 levels were measured (n = 6 for eac
represents the mean ± SD of three independent experiments. Significant d
#p < 0.05, ##p < 0.01 vs. the ANIT-treated group.such as MDR2 were formed in ANIT- intoxicanted rats.
However, intrinsic hepatocellular adaptive induction of
transporters in cholestasis is too weak to prevent on-
going liver injury [27]. Indeed, DNts pretreatment induced
mRNA and protein expressions of hepatic canalicular ex-
port transporters Bsep and Mdr2, beyond what was seen
following administration of ANIT alone. In addition, DNts
reversed ANIT-induced down-regulation of mRNA and
protein levels of Oatp1 and Ntcp for the attenuation of
cholestasis has been performed.
Mrp2, which is another key canalicular transporter,
belongs to ATP-binding cassette proteins localized to
the canalicular domain of the hepatocyte. Recent stud-
ies have demonstrated that, Mrp2 undergoes endocytic
retrieval from the canalicular membrane into an intracellu-
lar compartment in several models of cholestasis [20,28].
Our results showed that hepatic mRNA expression and
protein levels of MRP2 did not changed in ANIT-treated
rats. In contrast, Mrp2 in intracellular membranes wasin ANIT-induced cholestasis rats (n = 6 for each group). Hepatic
h group). Values are expressed as folds of control. Each bar represents
ifference between two groups, *p < 0.05, **p < 0.01 vs. control group;
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lack of change of Mrp2 content in mixed plasma mem-
branes in response to ANIT may be tentatively ex-
plained by the fact that intracellular accumulation of
Mrp2 in enriched microsomal membranes represents a
small fraction of the total amount of transporter in the cell
according to previous report [20]. It is possible that the
protective effects of DNts were through other alternative
mechanisms for the elevation of renal and biliary excretion
of bile acid and bilirubin with unchanged expression of
total Mrp2 in the kidney and liver.
Furthermore, Liver disease is often accompanied by
renal dysfunction. After ANIT treatment, renal mRNA
expressions of Mrp2, Mrp3, Mrp4 and Ostβ were sig-
nificantly up-regulated. In contrast, renal mRNA level
of Asbt was significantly down-regulated, accompanied
by increased concentrations of bile acid and bilirubin in
urine. These results indicated that adaptive responses to
cholestasis also occur in the kidney in an effort to elim-
inate excess bile acids and toxic compounds from circu-
lation which is according with previous report [29]. In
addition, DNts pretreatment further increased the renal
mRNA level of Ostβ in ANIT-intoxicated rats, accom-
panied by further increase in urinary excretion of bile
acid and bilirubin (Figure 7).Conclusions
In summary, Danning tablets provides protection from
ANIT-induced cholestasis with liver injury through adap-
tive responses in both the kidney and liver that enhance
the expressions of hepatic canalicular efflux transporters
(Bsep and Mdr2), renal efflux transporter Ostβ and bile
acid-detoxifying enzyme (Cyp2b1 and Ugt1a1) and attenu-
ate the hepatic Mrp2 translocation, accompanied by fur-
ther increase in urinary and biliary excretion of bile acid
and bilirubin.
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